Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2024-11-19 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
第四届董事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the first meeting of the fourth board of directors of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes election and appointment of board members and senior management, committee formations, internal governance adjustments, and other board-related decisions. The document references compliance with company law and articles of association, and it repeatedly mentions that these matters do not require shareholder meeting approval. The content focuses on board and management changes and governance structure updates. There is no financial data, earnings information, or audit content. The document is not a report itself but a formal announcement of board decisions. Therefore, it fits best under the category of Board/Management Information (MANG). The document length (7752 characters) and detailed content support this classification with high confidence.
2024-11-19 Chinese
第四届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the convening and attendance of the Supervisory Board meeting, election of the Supervisory Board chairman, and approval of stock option cancellations. It references related announcements published on the Beijing Stock Exchange website but does not contain financial statements or detailed financial data. The document is a formal meeting resolution announcement rather than a full report or financial filing. It fits best under Board/Management Information (MANG) as it concerns board-level decisions and management changes (election of chairman and stock option cancellations). The document length is short (1550 characters), consistent with a meeting resolution announcement rather than a full report.
2024-11-19 Chinese
董事会薪酬与考核委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Remuneration and Assessment Committee Working Rules" of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the composition, responsibilities, meeting rules, and procedures of the Remuneration and Assessment Committee under the Board of Directors. There is no financial data, no report of financial results, no voting results, no announcement of a report publication, and no mention of any regulatory filing or certification. The content is focused on governance practices related to board remuneration and assessment. Therefore, this document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 2801 characters, which is consistent with a detailed governance policy document rather than a brief announcement or a full financial report.
2024-11-19 Chinese
董事会战略与可持续发展委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Strategic and Sustainable Development Committee Working Rules" of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the establishment, composition, responsibilities, and procedural rules of a board committee. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, no capital changes, and no report publication. The document is a governance-related internal regulation about the board committee's operation and duties. This fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3104 characters, which is consistent with a detailed governance document rather than a brief announcement or a full annual report.
2024-11-19 Chinese
关于设立董事会薪酬与考核委员会并选举委员的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the establishment of a Board of Directors' Compensation and Assessment Committee and the election of its members. It details the committee's composition, responsibilities, and related governance rules. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management structural changes and governance practices. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2024-11-19 Chinese
北京浩天律师事务所关于北京三元基因药业股份有限公司注销2022年股权激励计划部分股票期权事项的法律意见书
Regulatory Filings
2024-11-19 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.